Larazotide, a breakthrough drug developed by Hangzhou Go Top Peptide Biotech Co., Ltd., is now available in the market as a potential treatment for celiac disease. As a leading manufacturer, supplier, and factory of biopharmaceutical products, Go Top Peptide Biotech has always been committed to finding innovative solutions to address unmet medical needs. Celiac disease is a chronic autoimmune disorder that affects the gastrointestinal tract, and it's estimated to affect 1 in 100 people worldwide. Larazotide is a therapeutic peptide-based drug that acts directly on the intestinal epithelium, helping to prevent gluten peptides from entering the bloodstream and ultimately causing an immune response. With clinical trials showing promising results, Larazotide has the potential to provide relief to millions of people suffering from celiac disease. As a leading peptide biotech company in China, Go Top Peptide Biotech is proud to have developed this ground-breaking drug, which is backed by years of research and development. We remain committed to advancing our pipeline of innovative therapeutics and improving the lives of patients around the world.